| 영문 | basal metabolic rate(BMR) | 한글 | 기초대사율 |
|---|---|---|---|
| 설명 | 표준 기초대사량과 비교했을 때 개체 기초대사량이 보이는 편차를 표시하는 지수. 기초대사량은 생명을 유지하는데 필요한 최소한의 에너지 대사량이며, 성과 연령이 동일한 건강인의 기초대사량은 체표면적에 비례한다. 이것을 체표면적의 법칙이라고 하며, 1882년 독일의 대사생리학자 M. 브루너에 의해 제창되었다. 체표면적은 신장과 체중에 의해 산출된다. 따라서 성-연령-신장-체중을 알면 표준기초량 Y가 산출되고 실제의 기초대사량 X는 산소소비량과 이산화탄소 발생량에서 산출된다. 그리고 X와 Y의 차이를 Y로 나눈 값(%)을 기초대사율이라고 한다. 경험적으로 얻은 BMR의 간단한 측정법도 있으며 다음과 같은 식으로 구한다. 이 식에서 맥폭이란 최고혈압과 최저혈압의 차를 말한다. BMR(%)=0.75(1분 맥박수 + 0.74×맥폭)－72. BMR이 10% 이내이면 정상범위, +10% 이상이면 기초대사항진, －10% 이하이면 기초대사 저하라고 한다. 기초대사는 공복시(식후 10시간 경과)에 안정된 상태에서 단위 시간당 이용되는 에너지의 양, 즉, 한 시간당, 몸 표면의 1m2당 또는 몸무게 1kg 당 칼로리로 나타낸다. 이것은 개인에 따라 다르며 장기간에는 거의 변화가 없지만 질병 등으로 인해 변동된다. 실측한 기초대사를 표준치와 비교함으로써 질병의 진단 등에 응용할 수 있다 BMR=(실측치-표준치)/표준치 ×100(%)로 나타낸다. |
||
| antag | antagonist |
|---|---|
| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
| FAA | folic acid antagonist; formaldehyde, acetic acid, alcohol |
| BMR | Basal Metabolic Rate; 기초대사율 |
| CLO | 의복의 열차단 단위 1 CLO; 기온 21℃, 기습 50 %, 기류 5cm/sec에서 Metabolic Rate 50 Kcal/m2/Hr로 피부온도가 ... |
| Ant | Antagonist |
|---|---|
| CA | calcium antagonist |
| GnRH-A | GnRH antagonist |
| H2-RA | Histamine-2 receptor antagonist |
| IL 1ra | IL 1 receptor antagonist |
| aldosterone antagonist | An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism. (05 Mar 2000) |
|---|---|
| antagonist | <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response. Origin: Gr. Antagonistes = an opponent (18 Nov 1997) |
| associated antagonist | One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action. (05 Mar 2000) |
| beta-adrenoreceptor antagonist | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| calcium antagonist | calcium channel-blocking agent |
| calcium channel antagonist | <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools. Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms. Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent. (12 May 2002) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
| muscarinic antagonist | Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine. (05 Mar 2000) |
| H2 antagonist | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
| insulin antagonist | Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin. (09 Oct 1997) |
| oestrogen antagonist | <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen. Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 May 2002) |
| enzyme antagonist | An antimetabolite or inhibitor of enzyme action. (05 Mar 2000) |
| folate antagonist | <pharmacology> One of a group of substances which blocks the formation of nucleotides that require the presence of folate (one of the B vitamins) before they can be made. The substance does this by blocking key steps in the reaction sequence. These substances are often used to treat cancer because fast-growing cancerous cells usually need to use the blocked reactions more than normal cells. (09 Oct 1997) |
| folic acid antagonist | <pharmacology> A chemical which inhibits a cells capacity to use folic acid and so prevent cell division, for example methotrexate. See: chemotherapy. (12 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|